


Transforming How Medicines are Developed and Delivered to Improve Efficacy, Safety and Global Accessibility

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Thin Film Freezing is designed to transform medicines into an elegant dry powder to overcome key limitations with current drug delivery:

- **Efficacy/Bioavailability:** A therapy is only as effective as its ability to reach its target. Thin Film Freezing transforms therapies with poor absorption into dry powder formulations that offer multiple targeted mechanisms of delivery, yielding improved bioavailability, faster onset of action and better efficacy.
- **Safety:** Therapies with poor solubility, nearly half of all medicines (NCEs), often require a high dose to generate an effective result, leading to increased adverse events and poor safety profiles. Thin Film Freezing converts poorly water-soluble therapies into a concentrated dry powder formulation that is >95% active drug, unlocking the potential to administer a lower effective dose with improved safety profile and reduced side effects.
- **Broad Applicability:** Thin Film Freezing technology has universal applicability to large and small molecules, vaccines and biologics. The stable dry powder generated through Thin Film Freezing can be applied for inhalation as well as intranasal, intraocular, and topical delivery.

[Watch this video](#) to learn more about how Thin Film Freezing works.



Product Portfolio

TFF's internal pipeline is focused on lung-directed drugs:

- **TFF VORI** is an inhaled dry powder version of voriconazole, an approved oral first-line antifungal used to treat invasive pulmonary aspergillosis (IPA). TFF's treatment is delivered directly to the site of infection to prevent IPA, reducing the risk of systemic exposure and drug-drug interactions and yielding better efficacy with a lower dose.
- **TFF TAC-LAC** is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine. Current therapies to prevent lung transplant rejection have low concentration in the lung, where they are most needed. TFF's inhalable version specifically targets lung tissue, yielding improved immunosuppression with less systemic exposure and risk of adverse events.
- **TFF Niclosamide** is an inhaled dry powder version of niclosamide, a potent antiviral used to treat infectious disease. Current oral Niclosamide has poor solubility, low absorption and bioavailability; TFF's formulation is optimized to treat viral infections through direct delivery to the mucosal system of the lung to improve overall efficacy, safety, and convenience of administration.
- **AUG-3387**: TFF is collaborating with Augmenta Bioworks to develop inhaled monoclonal antibody treatments that can be delivered directly to the lung where to neutralize viral infection, and can be delivered at home using a standard inhaler. The companies' lead candidate, AUG-3387, has been preclinically validated to neutralize SARS-CoV-2 infection in hamsters.



Depth and Breadth of Partnerships:

- TFF collaborates with a broad array of pharmaceutical companies, academic institutions, and government partners to leverage our disruptive technology and revolutionize healthcare around the globe.
- Partnerships aim to improve the efficacy and safety of approved therapeutics; broaden the potential of Thin Film Freezing technology to additional applications, including mRNA and vesicular stomatitis virus (VSV) vaccines; and to develop therapies that can be transported and administered with ease for future pandemic preparedness and biodefense.
- Current partnerships include many additional pipeline assets in early development, including 18 already identified candidates.

Robust Intellectual Property Portfolio:

- The scope of TFF Pharmaceuticals IP protection includes 120 patents issued and/or pending in the U.S. and internationally.

.....

TFF Pharmaceuticals' President and CEO: Glenn Mattes

NASDAQ: TFFP

Headquarters: Austin, Texas

Website: <https://tffpharma.com>

Follow us on [Twitter](#) and [LinkedIn](#)

.....

Company Contact:

Glenn Mattes

gmattes@tffpharma.com

Investor Relations Contact:

Corey Davis

cdavis@lifesciadvisors.com

Media Relations Contact:

Gwendolyn Schanker

gschanker@lifescicomms.com